Table 1 Relationship between Arg-1 and GPC-3 levels and clinicopathological characteristics in patients with intrahepatic cholangiocarcinoma
Clinical parameter | Arg-1 | P value | GPC-3 | P value | ||
|---|---|---|---|---|---|---|
Low (%), n = 207 | High, n = 30 | Low (%), n = 201 | High (%), n = 36 | |||
Age (years) | ||||||
 < 60 | 96 (46.4) | 12 (40.0) | 0.512 | 91 (45.3) | 17 (47.2) | 0.829 |
 ≥ 60 | 111 (53.6) | 18 (60.0) | 110 (54.7) | 19 (52.8) | ||
Gender | ||||||
 Female | 103 (49.8) | 9 (30.0) | *0.043 | 110 (54.7) | 15 (41.7) | 0.148 |
 Male | 104 (50.2) | 21 (70.0) | 91 (45.3) | 21 (58.3) | ||
HBsAg | ||||||
 Negative | 145 (70.0) | 27 (90.0) | *0.022 | 144 (71.6) | 28 (77.8) | 0.447 |
 Positive | 62 (32.4) | 3 (10.0) | 57 (28.4) | 8 (22.2) | ||
AFP (ng/mL) | ||||||
 < 25 | 140 (67.6) | 25 (83.3) | 0.081 | 140 (69.7) | 25 (69.4) | 0.980 |
 ≥ 25 | 67 (30.0) | 5 (16.7) | 61 (30.3) | 11 (30.6) | ||
CEA (ng/mL) | ||||||
 < 5 | 116 (56.0) | 18 (60.0) | 0.682 | 113 (56.2) | 21 (58.3) | 0.814 |
 ≥ 5 | 91 (44.0) | 12 (40.0) | 88 (43.8) | 15 (41.7) | ||
CA19-9 (IU/L) | ||||||
 < 37 | 128 (61.8) | 13 (43.3) | 0.054 | 127 (63.2) | 14 (38.9) | *0.006 |
 ≥ 37 | 79 (38.2) | 17 (56.7) | 74 (36.8) | 22 (61.1) | ||
TBIL (μmol/L) | ||||||
 < 17.1 | 80 (38.6) | 12 (40.0) | 0.887 | 81 (40.3) | 11 (30.6) | 0.269 |
 ≥ 17.1 | 127 (61.4) | 18 (60.0) | 120 (59.7) | 25 (69.4) | ||
ALB (g/L) | ||||||
 < 35 | 148 (71.5) | 15 (50.0) | 0.018 | 142 (70.6) | 21 (58.3) | 0.142 |
 ≥ 35 | 59 (28.5) | 15 (50.0) | 59 (29.4) | 15 (41.7) | ||
ALT (U/L) | ||||||
 < 40 | 82 (39.6) | 14 (46.7) | 0.462 | 83 (41.3) | 13 (36.1) | 0.560 |
 ≥ 40 | 125 (60.4) | 16 (53.3) | 118 (58.7) | 23 (63.9) | ||
Differentiation | ||||||
 W+M | 79 (38.2) | 14 (46.7) | 0.373 | 76 (37.8) | 17 (47.2) | 0.287 |
 P | 128 (61.8) | 16 (53.3) | 125 (62.2) | 19 (52.8) | ||
Tumor size (cm) | ||||||
 < 5 | 129 (62.3) | 13 (43.3) | *0.047 | 128 (63.7) | 14 (38.9) | *0.005 |
 ≥ 5 | 78 (37.7) | 17 (56.7) | 73 (36.3) | 22 (61.1) | ||
Tumor number | ||||||
 Single | 143 (69.1) | 24 (80.0) | 0.221 | 142 (70.6) | 25 (69.4) | 0.884 |
 Multiple | 64 (30.9) | 6 (20.0) | 59 (29.4) | 11 (30.6) | ||
Lymph node metastasis | ||||||
 No | 121 (58.5) | 13 (43.3) | 0.118 | 115 (57.2) | 19 (52.8) | 0.621 |
 Yes | 86 (41.5) | 17 (56.7) | 86 (43.3) | 17 (47.2) | ||
Vascular invasion | ||||||
 No | 120 (58.0) | 13 (43.3) | 0.131 | 114 (56.7) | 19 (52.8) | 0.661 |
 Yes | 87 (42.0) | 17 (56.7) | 87 (31.0) | 17 (47.2) | ||
Nerve invasion | ||||||
 No | 183 (88.4) | 23 (76.7) | 0.075 | 177 (88.1) | 29 (80.6) | 0.219 |
 Yes | 24 (11.6) | 7 (23.3) | 24 (11.9) | 7 (19.4) | ||
Extrahepatic metastasis | ||||||
 No | 128 (61.8) | 17 (56.7) | 0.587 | 123 (61.2) | 22 (61.1) | 0.992 |
 Yes | 79 (38.2) | 13 (43.3) | 78 (38.8) | 14 (38.9) | ||
TNM | ||||||
 I+II | 114 (55.1) | 13 (43.3) | 0.228 | 109 (54.2) | 18 (50.0) | 0.639 |
 III+IV | 93 (44.9) | 17 (56.7) | 92 (45.8) | 18 (50.0) | ||
Chemotherapy | ||||||
 No | 112 (58.9) | 17 (56.7) | 0.813 | 118 (58.7) | 21 (58.3) | 0.967 |
 Yes | 85 (41.1) | 13 (43.3) | 83 (41.3) | 15 (41.7) | ||